Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
CNO Financial (CNO) Reports Strong Q3 2026 Earnings With Guidance Raise

CNO Financial (CNO) Reports Strong Q3 2026 Earnings With Guidance Raise

Key Takeaways

  • CNO Financial Group reported third-quarter 2026 net income of $161.1 million, or $1.71 per diluted share, up sharply from $23.1 million, or $0.24 per share, in the prior-year quarter.
  • Net operating income, a non-GAAP measure, came in at $179.1 million, or $1.90 per diluted share, up roughly 47% year over year.
  • Total revenue of about $1.09 billion exceeded the consensus estimate near $1.01 billion, even as it declined from $1.19 billion a year earlier.
  • Management raised its full-year 2026 operating earnings per share (EPS) guidance, lifting the midpoint to about 9% above its prior outlook.
  • The quarter marked a 17th consecutive quarter of sales growth, and the company repurchased $60 million of common stock.

Why These Results Stand Out

CNO Financial Group serves middle-income Americans with life and health insurance along with retirement products. Its quarterly updates give investors a clear view of underwriting discipline, sales trends, and how the company manages its capital. This particular release stood out because the prior-year quarter included a sizable goodwill impairment, which made the year-over-year profit comparison look especially strong. Beyond the headline figures, I was interested in whether CNO would keep its streak of sales growth alive, lift operating profitability, and put capital to work through buybacks and reinsurance. The numbers also offered an early look at how higher interest rates are influencing book value and fixed indexed annuity liabilities.

Breaking Down the Quarter

For the third quarter ended September 30, 2026, CNO posted net income of $161.1 million, or $1.71 per diluted share, versus $23.1 million, or $0.24 per share, a year earlier. Net operating income reached $179.1 million, or $1.90 per diluted share, roughly 47% higher than the prior year. Total revenue came in near $1.09 billion, topping the consensus estimate of about $1.01 billion even though it fell from $1.19 billion in the year-ago period. Operating EPS of $1.90 comfortably beat analyst forecasts around $1.10. Significant items added a favorable $44.9 million to both net income and net operating income.

Book value per common share slipped to $25.34 from $27.24 a year earlier, mainly because of the impact of higher interest rates on the investment portfolio. The consolidated statutory risk-based capital ratio stood at an estimated 374%.

How the Market Responded

Shares moved higher right after the release, climbing about 2% to near $56 in early trading. The wide beat on operating EPS and the upward revision to full-year guidance drove most of the positive reaction. A reinsurance deal covering roughly $270 million of Colonial Penn in-force graded benefit life statutory reserves also pointed to progress on capital efficiency. Heading into the report, sentiment had already been constructive given the long record of sales growth, and these results reinforced that view with both an earnings beat and a guidance increase. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Comes Next

With the beat and raised guidance in hand, attention now turns to whether CNO can maintain operating momentum through the rest of 2026 and into 2027. The new full-year operating EPS outlook, with its midpoint about 9% above the earlier target, raises the bar for execution and underwriting stability. Capital deployment will stay in focus: about $240 million remains under the share repurchase authorization, and the company has a history of active buybacks that can support per-share results. The third reinsurance transaction with its Bermuda affiliate shows continued attention to risk management and capital release. Interest-rate effects on book value through accumulated other comprehensive losses remain worth watching, even as higher rates may eventually lift investment income. The TechMod technology initiative continues to generate expenses as it rolls out. Finally, sales trends across the core segments deserve attention—the 17-quarter growth streak has been a consistent theme, and any shift there could influence how the market values the stock.

My Take on AI Tools for Research

I often turn to Tickeron’s AI tools when reviewing earnings like these to quickly compare sector trends and spot similar setups. Their AI Daily Buy/Sell Signals and AI Trend Prediction Engine help me stay objective without spending hours on manual screens. It is a practical part of my routine for staying on top of names in insurance and financial services.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CNO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CNO's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for CNO moved out of overbought territory on November 03, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 instances where the indicator moved out of the overbought zone. In 20 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a move down at 50%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CNO as a result. In 44 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 50%.

The Moving Average Convergence Divergence Histogram (MACD) for CNO turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 24 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 50%.

CNO moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for CNO crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.

Following a +1.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNO advanced for three days, in 210 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

CNO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 198 of 296 cases where CNO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CNO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.980) is normal, around the industry mean (1.337). P/E Ratio (18.733) is within average values for comparable stocks, (19.773). Projected Growth (PEG Ratio) (0.210) is also within normal values, averaging (0.463). Dividend Yield (0.013) settles around the average of (0.047) among similar stocks. P/S Ratio (1.156) is also within normal values, averaging (1.303).

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are MetLife (NYSE:MET), Prudential Financial (NYSE:PRU), Lincoln National Corp (NYSE:LNC), Genworth Financial (NYSE:GNW).

Industry description

Life insurance companies mainly sell policies that pay a death benefit as a lump sum upon the death of the insured to their beneficiaries. Life insurance policies may be sold as term life, (which guarantees payment of a stated death benefit and expires at the end of a specified term) or permanent /typically whole life (which is more expensive but lasts a lifetime and carries a cash accumulation component). Life insurance firms may also sell long-term disability policies that help to replace the insured individual’s income if they become sick or disabled. Health insurance, on the other hand, helps pay for medical expenses. Anthem, Inc., MetLife, Inc. and Aflac Incorporated are some of the largest U.S. companies in this industry.

Market Cap

The average market capitalization across the Life/Health Insurance Industry is 18.5B. The market cap for tickers in the group ranges from 228.36K to 140.68B. CILJF holds the highest valuation in this group at 140.68B. The lowest valued company is GWGHQ at 228.36K.

High and low price notable news

The average weekly price growth across all stocks in the Life/Health Insurance Industry was -7%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -9%. SNFCA experienced the highest price growth at 0%, while ABX experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Life/Health Insurance Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was 50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 65
Price Growth Rating: 56
SMR Rating: 91
Profit Risk Rating: 61
Seasonality Score: 9 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of health and life insurance services

Industry LifeHealthInsurance

Industry
Life Or Health Insurance
Address
11299 Illinois Street
Phone
+1 317 817-6100
Employees
3300
Web
https://www.cnoinc.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.